This study suggests that benserazide may have potential as a chemosensitizer in cancer treatment by enhancing the anti-cancer effect of paclitaxel through the inhibition of S-sulfhydration of SIRT1 and enhancing the anti-angiogenic effect of paclitaxel through downregulation of HIF-1α/VEGF signaling pathway proteins expression, as shown in Figure 10. This evidence concerns the gene HIF1A and cancer.